These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Ocular Drug Delivery: Present Innovations and Future Challenges. Gote V; Sikder S; Sicotte J; Pal D J Pharmacol Exp Ther; 2019 Sep; 370(3):602-624. PubMed ID: 31072813 [TBL] [Abstract][Full Text] [Related]
23. Nanocarriers Based Ocular Therapeutics: Updates, Challenges and Future Prospectives. Kaushal U; Kaur M; Nagpal M; Bhuyan M; Gounder KP Curr Drug Res Rev; 2023; 15(1):15-28. PubMed ID: 36100986 [TBL] [Abstract][Full Text] [Related]
24. Advances and limitations of drug delivery systems formulated as eye drops. Jumelle C; Gholizadeh S; Annabi N; Dana R J Control Release; 2020 May; 321():1-22. PubMed ID: 32027938 [TBL] [Abstract][Full Text] [Related]
25. Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration. Silva MM; Calado R; Marto J; Bettencourt A; Almeida AJ; Gonçalves LMD Mar Drugs; 2017 Dec; 15(12):. PubMed ID: 29194378 [TBL] [Abstract][Full Text] [Related]
26. Posterior Segment Ophthalmic Drug Delivery: Role of Muco-Adhesion with a Special Focus on Chitosan. Burhan AM; Klahan B; Cummins W; Andrés-Guerrero V; Byrne ME; O'Reilly NJ; Chauhan A; Fitzhenry L; Hughes H Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683978 [TBL] [Abstract][Full Text] [Related]
27. Recent developments in ocular drug delivery. Chen H J Drug Target; 2015; 23(7-8):597-604. PubMed ID: 26453157 [TBL] [Abstract][Full Text] [Related]
28. Nanoparticles for drug delivery to the anterior segment of the eye. Janagam DR; Wu L; Lowe TL Adv Drug Deliv Rev; 2017 Dec; 122():31-64. PubMed ID: 28392306 [TBL] [Abstract][Full Text] [Related]
29. A review on recent drug delivery systems for posterior segment of eye. Nayak K; Misra M Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375 [TBL] [Abstract][Full Text] [Related]
30. Recent Advances in Ocular Drug Delivery, with Special Emphasis on Lipid Based Nanocarriers. Sah AK; Suresh PK Recent Pat Nanotechnol; 2015; 9(2):94-105. PubMed ID: 27009124 [TBL] [Abstract][Full Text] [Related]
31. A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. Wong CW; Metselaar JM; Storm G; Wong TT Br J Ophthalmol; 2021 Dec; 105(12):1617-1622. PubMed ID: 33127826 [TBL] [Abstract][Full Text] [Related]
32. Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma. Wu KY; Wang XC; Anderson M; Tran SD Molecules; 2024 May; 29(10):. PubMed ID: 38792122 [TBL] [Abstract][Full Text] [Related]
33. Drug delivery to the eye: what benefits do nanocarriers offer? Joseph RR; Venkatraman SS Nanomedicine (Lond); 2017 Mar; 12(6):683-702. PubMed ID: 28186436 [TBL] [Abstract][Full Text] [Related]
34. Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases. Navarro-Partida J; Castro-Castaneda CR; Santa Cruz-Pavlovich FJ; Aceves-Franco LA; Guy TO; Santos A Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34065059 [TBL] [Abstract][Full Text] [Related]
35. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye. Bisht R; Jaiswal JK; Rupenthal ID Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808 [TBL] [Abstract][Full Text] [Related]
36. Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers. de Oliveira IF; Barbosa EJ; Peters MCC; Henostroza MAB; Yukuyama MN; Dos Santos Neto E; Löbenberg R; Bou-Chacra N Int J Pharm; 2020 Nov; 589():119831. PubMed ID: 32877729 [TBL] [Abstract][Full Text] [Related]
37. Designing lipid nanoparticles for topical ocular drug delivery. Alvarez-Trabado J; Diebold Y; Sanchez A Int J Pharm; 2017 Oct; 532(1):204-217. PubMed ID: 28893582 [TBL] [Abstract][Full Text] [Related]
38. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Loftsson T; Sigurdsson HH; Konrádsdóttir F; Gísladóttir S; Jansook P; Stefánsson E Pharmazie; 2008 Mar; 63(3):171-9. PubMed ID: 18444504 [TBL] [Abstract][Full Text] [Related]
39. Ocular delivery systems for topical application of anti-infective agents. Duxfield L; Sultana R; Wang R; Englebretsen V; Deo S; Rupenthal ID; Al-Kassas R Drug Dev Ind Pharm; 2016 Jan; 42(1):1-11. PubMed ID: 26325119 [TBL] [Abstract][Full Text] [Related]
40. Ocular Drug Delivery: a Comprehensive Review. Ahmed S; Amin MM; Sayed S AAPS PharmSciTech; 2023 Feb; 24(2):66. PubMed ID: 36788150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]